First-line bevacizumab-containing therapy for HER2-negative metastatic breast cancer: final results from a prospective German study
Aim: The German ML21165 study evaluated bevacizumab-containing therapy for metastatic breast cancer (mBC) in routine oncology practice. Patients and Methods: Patients received bevacizumab with chemotherapy until disease progression, unacceptable toxicity or consent withdrawal. Pre-specified end-poin...
Gespeichert in:
| 1. Verfasser: | |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
March 2016
|
| In: |
Anticancer research
Year: 2016, Jahrgang: 36, Heft: 3, Pages: 967-974 |
| ISSN: | 1791-7530 |
| Online-Zugang: | Verlag, Volltext: http://ar.iiarjournals.org/content/36/3/967
|
| Verfasserangaben: | Andreas Schneeweiss, Frank Förster, Hans Tesch, Bahriye Aktas, Oleg Gluz, Matthias Geberth, Martin M. Hertz-Eichenrode, Winfried Schönegg, Claudia Schumacher, Andreas Kutscheidt, Claudia Kiewitz, Sandra Klawitter and Marcus Schmidt |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 166531639X | ||
| 003 | DE-627 | ||
| 005 | 20230427000807.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 190513s2016 xx |||||o 00| ||eng c | ||
| 035 | |a (DE-627)166531639X | ||
| 035 | |a (DE-599)KXP166531639X | ||
| 035 | |a (OCoLC)1341212903 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Schneeweiss, Andreas |d 1961- |e VerfasserIn |0 (DE-588)109972554 |0 (DE-627)632849630 |0 (DE-576)327251859 |4 aut | |
| 245 | 1 | 0 | |a First-line bevacizumab-containing therapy for HER2-negative metastatic breast cancer |b final results from a prospective German study |c Andreas Schneeweiss, Frank Förster, Hans Tesch, Bahriye Aktas, Oleg Gluz, Matthias Geberth, Martin M. Hertz-Eichenrode, Winfried Schönegg, Claudia Schumacher, Andreas Kutscheidt, Claudia Kiewitz, Sandra Klawitter and Marcus Schmidt |
| 264 | 1 | |c March 2016 | |
| 300 | |a 8 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 13.05.2019 | ||
| 520 | |a Aim: The German ML21165 study evaluated bevacizumab-containing therapy for metastatic breast cancer (mBC) in routine oncology practice. Patients and Methods: Patients received bevacizumab with chemotherapy until disease progression, unacceptable toxicity or consent withdrawal. Pre-specified end-points were safety and efficacy [response rate, progression-free survival (PFS) and overall survival (OS)]. Results: Between May 2007 and September 2009, 865 patients received first-line bevacizumab plus paclitaxel for mBC, of whom 16% were aged ≥70 years and 9% had ECOG performance status of 2 or more. At data cut-off (median of 15.9 months' follow-up), the median PFS was 9.6 months [95% confidence interval (CI)=9.0-10.4 months] and the median OS was 21.6 months (95% CI=19.4-23.5 months). The most common non-haematological adverse drug reactions of grade 3 or more were pain (9%), hypertension (5%), sensory neuropathy (3%) and proteinuria (3%). Prolonged bevacizumab was well-tolerated. Conclusion: The efficacy and safety of first-line bevacizumab-paclitaxel in routine oncology practice is consistent with results from randomized trials. | ||
| 650 | 4 | |a Anti-angiogenic | |
| 650 | 4 | |a bevacizumab | |
| 650 | 4 | |a first-line | |
| 650 | 4 | |a metastatic breast cancer | |
| 650 | 4 | |a vascular endothelial growth factor | |
| 773 | 0 | 8 | |i Enthalten in |t Anticancer research |d Kapandriti, Attiki, Greece : International Institute of Anticancer Research, 2004 |g 36(2016), 3, Seite 967-974 |h Online-Ressource |w (DE-627)387478493 |w (DE-600)2145376-7 |w (DE-576)358408717 |x 1791-7530 |7 nnas |a First-line bevacizumab-containing therapy for HER2-negative metastatic breast cancer final results from a prospective German study |
| 773 | 1 | 8 | |g volume:36 |g year:2016 |g number:3 |g pages:967-974 |g extent:8 |a First-line bevacizumab-containing therapy for HER2-negative metastatic breast cancer final results from a prospective German study |
| 856 | 4 | 0 | |u http://ar.iiarjournals.org/content/36/3/967 |x Verlag |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20190513 | ||
| 993 | |a Article | ||
| 994 | |a 2016 | ||
| 998 | |g 109972554 |a Schneeweiss, Andreas |m 109972554:Schneeweiss, Andreas |d 910000 |d 910400 |d 50000 |e 910000PS109972554 |e 910400PS109972554 |e 50000PS109972554 |k 0/910000/ |k 1/910000/910400/ |k 0/50000/ |p 1 |x j | ||
| 999 | |a KXP-PPN166531639X |e 3475571110 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"name":{"displayForm":["Andreas Schneeweiss, Frank Förster, Hans Tesch, Bahriye Aktas, Oleg Gluz, Matthias Geberth, Martin M. Hertz-Eichenrode, Winfried Schönegg, Claudia Schumacher, Andreas Kutscheidt, Claudia Kiewitz, Sandra Klawitter and Marcus Schmidt"]},"language":["eng"],"recId":"166531639X","person":[{"role":"aut","family":"Schneeweiss","given":"Andreas","display":"Schneeweiss, Andreas"}],"note":["Gesehen am 13.05.2019"],"type":{"media":"Online-Ressource","bibl":"article-journal"},"title":[{"title_sort":"First-line bevacizumab-containing therapy for HER2-negative metastatic breast cancer","title":"First-line bevacizumab-containing therapy for HER2-negative metastatic breast cancer","subtitle":"final results from a prospective German study"}],"physDesc":[{"extent":"8 S."}],"id":{"eki":["166531639X"]},"relHost":[{"name":{"displayForm":["International Institute of Anticancer Research"]},"recId":"387478493","id":{"zdb":["2145376-7"],"eki":["387478493"],"issn":["1791-7530"]},"physDesc":[{"extent":"Online-Ressource"}],"title":[{"title_sort":"Anticancer research","title":"Anticancer research","subtitle":"international journal of cancer research and treatment"}],"origin":[{"publisherPlace":"Kapandriti, Attiki, Greece","dateIssuedKey":"2004","dateIssuedDisp":"2004-","publisher":"International Institute of Anticancer Research"}],"part":{"year":"2016","volume":"36","text":"36(2016), 3, Seite 967-974","issue":"3","extent":"8","pages":"967-974"},"language":["eng"],"pubHistory":["Nachgewiesen 24.2004 -"],"note":["Gesehen am 26.02.13"],"disp":"First-line bevacizumab-containing therapy for HER2-negative metastatic breast cancer final results from a prospective German studyAnticancer research","type":{"media":"Online-Ressource","bibl":"periodical"}}],"origin":[{"dateIssuedDisp":"March 2016","dateIssuedKey":"2016"}]} | ||
| SRT | |a SCHNEEWEISFIRSTLINEB2016 | ||